Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Read more about Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. Read more about Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Read more about Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. Read more about Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort.
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Read more about Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
Active Surveillance in Michigan: What Is Possible When Payers Partner with Physicians. Read more about Active Surveillance in Michigan: What Is Possible When Payers Partner with Physicians.
Reply to Sandra Patricia García Nader, Sebastián Peña Rodríguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol Read more about Reply to Sandra Patricia García Nader, Sebastián Peña Rodríguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Read more about Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Prostate-Specific Antigen Screening in Transgender Patients. Read more about Prostate-Specific Antigen Screening in Transgender Patients.
Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm. Read more about Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm.
